You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Taking resistance from the bench to the clinic: a focus on dolutegravir▼ GoTo Top Close

In this webinar ViiV Healthcare’s team of experts present the differentiating features of dolutegravir-based regimens for the treatment of HIV, including the science behind a high barrier to resistance and the clinical implications.

Taking Resistance from the Bench Side to the Clinic: A Focus on Dolutegravir

Presented by Dr. Romina P. Querica, Global Director of Clinical Virology and Early Drug Development, ViiV Healthcare.

TRIUMEQ is indicated for the treatment of HIV-infected adults and adolescents above 12 years of age weighing at least 40kg.

Before initiating treatment with abacavir-containing products, HLA-B*5701 status must always be documented. Abacavir should not be used in patients known to carry the HLA-B*5701 allele due to the risk of hypersensitivity reaction.

Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children above 6 years of age.

Women of childbearing potential (WOCBP) should undergo pregnancy testing before initiation of dolutegravir. WOCBP who are taking dolutegravir should use effective contraception throughout treatment.1

Triumeq

(dolutegravir/abacavir/lamivudine)

Product information

Prescribing information

References:

  1. TIVICAY Summary of Product Characteristics. Available from: https://www.medicines.ie/medicines/tivicay-film-coated-tablets-33993/, last accessed: December 2018.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Trade marks are owned by or licensed to the ViiV Healthcare group of companies.